Tuesday, October 27, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 26, 2026

Large Language Model Market Forecasted to Reach USD 149.89 Billion by 2035 Driven by AI Automation and Open-Source Adoption

View original at globenewswire.com
Large Language Model Market Forecasted to Reach USD 149.89 Billion by 2035 Driven by AI Automation and Open-Source Adoption Ottawa, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The customer service segment is anticipated to register the fastest CAGR during the forecast period

    80% confidence

  • The healthcare segment held a significant share in 2025, while the finance segment is projected to expand at a rapid pace

    80% confidence

  • The cloud segment is expected to grow at the highest rate throughout the study period

    80% confidence

  • Chatbots and virtual assistants dominated the market with a 28% share in 2025

    80% confidence

  • Asia Pacific is expected to witness the highest growth rate over the forecast period

    80% confidence

  • Growing automation across various tasks and strong focus on accelerating decision-making increase demand for LLM

    80% confidence

  • The global large language model market will grow from USD 10.57 billion in 2026 to nearly USD 149.89 billion by 2035, expanding at a CAGR of 34.44% from 2026 to 2035

    80% confidence

  • North America led the global large language model market in 2025, capturing a 33% revenue share

    80% confidence

  • The U.S. large language model market size is expected to cross around USD 37.98 billion by 2035, increasing from USD 2.62 billion in 2026, growing at a CAGR of 34.78% from 2026 to 2035

    80% confidence

  • The on-premises segment accounted for a major 59% share in 2025

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com